Clinical Trials on Triple-Negative Breast Carcinoma in United States

Total 1601 results

Adlai Nortye Biopharma Co., Ltd.
Merck Sharp & Dohme LLC

Active, not recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Cervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)

United States, France
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Terminated

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (BATON-BC)

Triple Negative Breast Cancer

Germany, Taiwan, Spain, Ukraine, Australia, Korea, Republic of, Canada, United States, Italy, Bahamas
Memorial Sloan Kettering Cancer Center

Recruiting

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Non Small Cell Lung Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Non-Small Cell Lung Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Recruiting

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Leptomeningeal Disease

United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Formation Biologics

Terminated

AVID100 in Advanced Epithelial Carcinomas

Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Solid Tumor, Adult

United States
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Queen Mary University of London
AstraZeneca; Cancer Research UK

Unknown

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (TORCMEK)

Squamous Cell Lung Cancer | Triple-Negative Breast Cancer | Non-squamous Cell Lung Cancer With KRAS Mutations | Non-squamous Cell Lung Cancer With Wild-type KRAS

United Kingdom
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditions

United States
GlaxoSmithKline

Active, not recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

Neoplasms, Breast

United States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC... and other conditions

United States
Royal Marsden NHS Foundation Trust
Pfizer; Breast Cancer Now

Active, not recruiting

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

Gastric Cancer | Triple Negative Breast Cancer | Lobular Breast Carcinoma | CDH1 Gene Mutation

United Kingdom
National Cancer Institute (NCI)

Completed

Phase II ABT-888 With Cyclophosphamide

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Triple-Negative Breast Cancer | Serous Carcinoma Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditions

United States
Baylor Breast Care Center

Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE)

Breast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer Invasive

United States
Pure Biologics S.A.
Presage Biosciences

Recruiting

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Soft Tissue Sarcoma Adult

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer

Invasive Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | HER2 Positive Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Stage IV Breast Cancer | Invasive Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative...

United States
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
Synta Pharmaceuticals Corp.

Completed

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (Enchant)

Breast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment

Spain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
National Cancer Institute (NCI)

Terminated

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Inflammatory Carcinoma

United States
Hefei TG ImmunoPharma Co., Ltd.

Recruiting

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Melanoma | Colorectal Cancer | Ovarian Cancer | Triple Negative Breast Cancer

United States
Innocrin Pharmaceutical
National Cancer Institute (NCI)

Completed

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Prostate Cancer

United States
Calithera Biosciences, Inc

Terminated

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Colorectal Cancer | Solid Tumor | CRC | TNBC - Triple-Negative Breast Cancer | ccRCC | RCC

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Breast Cancer | Triple Negative Breast Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Withdrawn

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Chimerix

Withdrawn

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Advanced Colorectal Cancer | Advanced Glioblastoma | Advanced Triple-negative Breast Cancer | Advanced Non-small Cell Lung Cancer

United States
Calithera Biosciences, Inc

Terminated

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Advanced Solid Tumors | Triple-Negative Breast Neoplasms | Head and Neck Carcinoma, Squamous Cell

Spain, United States, Italy, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

United States
Simcha IL-18, Inc.
Merck Sharp & Dohme LLC

Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Melanoma | Carcinoma | Renal Cell Carcinoma | Cancer | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple-negative Breast Cancer | MSI-High

United States
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Weill Medical College of Cornell University

Recruiting

De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You (DIGNITY)

Breast Cancer

United States
University of Chicago

Active, not recruiting

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Breast Cancer | Triple Negative Breast Neoplasms

United States
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); Breast... and other collaborators

Terminated

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

Triple Negative Breast Neoplasms

United States
Dana-Farber Cancer Institute
Genentech, Inc.; Stand Up To Cancer

Active, not recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast Cancer | Triple Negative Breast Cancer | Circulating Tumor DNA | Residual Cancer

United States
Duke University
National Comprehensive Cancer Network

Withdrawn

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC (IMGN853)

Breast Cancer Triple Negative

United States
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
University of Wisconsin, Madison
National Cancer Institute (NCI)

Terminated

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Breast Neoplasms | Triple Negative Breast Neoplasms

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Active, not recruiting

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Breast Cancer

United States
AstraZeneca

Completed

Study of Tremelimumab in Patients With Advanced Solid Tumors

Pancreatic Ductal Adenocarcinoma | Triple-negative Breast Cancer | Urothelial Bladder Cancer

United States, Belgium, Korea, Republic of, Poland, Netherlands
Sanofi
UNC Lineberger Comprehensive Cancer Center

Completed

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Brain Metastases | Estrogen Receptor Negative (ER-Negative) Breast Cancer | Progesterone Receptor Negative (PR-Negative) Breast Cancer | Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

United States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
AstraZeneca

Completed

AZD8186 First Time In Patient Ascending Dose Study

Advanced Castrate-resistant Prostate Cancer CRPC | Squamous Non-Small Cell Lung Cancer sqNSCLC | Triple Negative Breast Cancer TNBC

Spain, Canada, United States, United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
Indiana University
Breast Cancer Research Foundation

Withdrawn

Breast Cancer BRCA1 Carriers: a Pilot Study

High-grade Serous Ovarian Cancer | BRCA1 Mutation | TNBC - Triple-Negative Breast Cancer

United States

Clinical Trials on Triple-Negative Breast Carcinoma in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations